Redeye comments on Smart Eye’s acquisition of Sightic, which removes the most meaningful competitive...
Redeye provides an update following Q-linea’s Q4 2025 report.
* First signs of Swedish project market recovery * Could add ~15% of '25e EBITA N3Y * Ready for M&A,...
Redeye leaves a comment following OncoZenge’s announcement of the completed readout from its UCLA-le...
Redeye comments on Coffee Stain Group’s Q3 2025/2026 results, which were better than expected on bot...
Sleep Cycle’s Q4 report was in line with our top-line expectations but revealed a steeper-than-antic...
* Net sales SEK 557m, +5% vs ABGSCe, +4% vs Factset cons.
While the current valuation profile of Vitrolife requires more than the current stagnant growth prof...
Redeye updates its estimates and valuation after Lifco’s Q4 2025 report.
Redeye retains its positive view of Addnode following a solid Q4 report.
* Q4 growth partly offset by SMS volumes * Raising EBITA by 7-6% for '26e-'27e * 11-9x EV/EBITA on '...
We lower sales by 4% and cut EBIT by SEK 4-12m in 2026E-28E.
Redeye is optimistic about the new investigator-sponsored phase II trial in respiratory infections, ...
Redeye comments on ExpreS2ion’s announcement of updated Phase I immunogenicity data for its HER2-tar...
Siljansvik announced that its majority-owned subsidiary Dala Vind has received an additional milesto...
Vaisala reports Q4 results on Feb 12. We believe Vaisala’s FY’25 EBITA improved only slightly y/y, w...
Substansvärdet uppgick till 67 kr per aktie och minskade med 2 % jämfört med föregående kvartal, exk...
* 24% organic sales growth in Q4 (ABGSCe +27%) Adj.
Q4 sales was SEK 45m (-6% vs. SEB at SEK 48m) corresponding to 24% y/y growth at constant exchange r...
Vitrolife’s Q4 report came in very close to our projections, reflecting modest underlying growth and...